<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Twenty-four patients with <z:hpo ids='HP_0001915'>aplastic anemia</z:hpo> (19 severe: 5 moderate) were treated with combined immunosuppression consisting of antithymocyte globulin (ATG: Lymphoser Berna, Swiss Serum and Vaccine Institute Berne) and high-dose <z:chebi fb="0" ids="6888">methylprednisolone</z:chebi> </plain></SENT>
<SENT sid="1" pm="."><plain><z:chebi fb="1" ids="4315">Danazol</z:chebi> or meptiostane was administered concurrently for at least 3 months </plain></SENT>
<SENT sid="2" pm="."><plain>Three batches of ATG were used, two were not absorbed with thrombocytes and one was absorbed with thrombocytes for the prevention of <z:hpo ids='HP_0001873'>thrombocytopenia</z:hpo> </plain></SENT>
<SENT sid="3" pm="."><plain>Nine of 20 evaluable patient (45%) had sustained improvement in hematopoiesis within 3 months of treatment </plain></SENT>
<SENT sid="4" pm="."><plain>Nine of 14 patients (64%) showed a response to ATG without thrombocyte absorption, on the other hand, none of 6 patients responded to ATG with thrombocyte absorption </plain></SENT>
<SENT sid="5" pm="."><plain>By life table analysis, the 3 year probability of survival was 81 +/- 27% after the combined immunosuppressive therapy </plain></SENT>
<SENT sid="6" pm="."><plain>These results indicated that ATG therapy was very effective in Japanese patients with <z:hpo ids='HP_0001915'>aplastic anemia</z:hpo> </plain></SENT>
</text></document>